ISRCTN10628149
Completed
Not Applicable
A randomised, double-blind, placebo-controlled clinical trial of a Compound Herbal Preparation (CHP) in the treatment of children with Attention-Deficit Hyperactivity Disorder (ADHD)
Etz-HaChayim Clinic (Israel)0 sites120 target enrollmentOctober 30, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Etz-HaChayim Clinic (Israel)
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. One hundred and twenty children, aged 6 \- 12 years
- •2\. Recruited from the Sheba Medical Center Clinic for Paediatric Behavioural Disorders
- •3\. No history of prior treatment for ADHD
- •4\. Diagnosed with ADHD\-PI or ADHD\-H by a specialised paediatric psychiatrist, based on Diagnostic and Statistical Manual of Mental Disorders \- Fourth Edition (DSM\-IV) criteria and assessment interviews with participants and their parents
- •5\. Children meeting the DSM\-IV criteria for inclusion in the study were evaluated with the Test of Variables of Attention (TOVA). Inclusion required a standard score of below 85 on at least one of the TOVA subscales
Exclusion Criteria
- •1\. Medical conditions, other than ADHD, causing inattention and hyperactivity (i.e., anaemia, hypoglycaemia, thyroid disorders, etc.)
- •2\. A standard score of over 85 on all of the TOVA (Test of Variables of Attention) subscales
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Randomised efficacy and safety clinical trial of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass polleSeasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposureMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2019-001517-16-CZAllergy Therapeutics (UK) Ltd.1,342
Active, not recruiting
Phase 1
Randomised efficacy and safety clinical trial of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass polleSeasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposureMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2019-001517-16-ATAllergy Therapeutics (UK) Ltd.1,342
Active, not recruiting
Phase 1
Randomised efficacy and safety clinical trial of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass polleSeasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposureMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2019-001517-16-HUAllergy Therapeutics (UK) Ltd.1,204
Not yet recruiting
Not Applicable
A randomised, double-blind, placebo-controlled clinical trial to determine the effects of MaZiRenWan granules on functional constipation and constipation-predominant irritable bowel syndromeITMCTR2100004417Hong Kong Baptist University
Active, not recruiting
Phase 1
Randomised efficacy and safety clinical trial of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass polleSeasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposureMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2019-001517-16-PLAllergy Therapeutics (UK) Ltd.1,342